Promising results from a phase 2 study prompted the ongoing phase 3 ESSENCE trial, to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage 2 or 3 fibrosis. Sanyal et al.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

Semaglutide presents a promising, multi-targeted therapeutic option for addressing the hepatic and systemic consequences of MASH, though final conclusions on long-term clinical outcomes await the ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

“The results from this landmark study across 37 countries provide strong evidence that semaglutide can help patients with MASH by not only improving liver health, but also addressing the ...